Clinical trial · Observational
Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the LANA bio-collection is to collect samples from patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) or or high-risk myelodysplastic syndrome (MDS) to facilitate access to the leukemic or myelodysplastic cells for the research teams of the National Institute of Health and Medical Research (INSERM). To do this, an additional blood or bone marrow sample to those planned in the context of patient care will be collected after signing consent. These samples will then be sent directly to the INSERM teams for immediate analysis with the aim to conduct research aimed at a better understanding of AML, ALL or MDS and improving treatments
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoid Leukemia | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| Acute Myeloid Leucemia | — | UNRESOLVED | — |
| High-risk Myelodysplastic Syndrome (MDS) | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with high-risk AML, ALL or MDS
- description
- Patients with high-risk AML, ALL or MDS treated in the hematology department of Nantes University Hospital. According to the needs of ongoing biological studies, additional volumes may be collected during blood and bone marrow sampling for diagnosis or relapse at inclusion , with up to one additional sample each month for three months following inclusion
Primary outcomes (1)
- measure
- Characterization of the tumor and its microenvironment for AML, ALL or MDS in order to identify novel biomarkers or therapeutic targets
- timeFrame
- One year after inclusion
- description
- Identify genetic polymorphisms associated with an increased risk of developing AML or ALL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient of legal age affected by AML, ALL or MDS regardless of the time of treatment * Patient who has signed the consent form. * Patient affiliated with a social security system. Exclusion Criteria: * Minor patients. * Adults under guardianship. * Protected persons
References
Publications (0)
Data not yet available